See more : RJD Green, Inc. (RJDG) Income Statement Analysis – Financial Results
Complete financial analysis of Laboratorios Richmond S.A.C.I.F. (RICH.BA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Laboratorios Richmond S.A.C.I.F., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Temenos AG (0QOA.L) Income Statement Analysis – Financial Results
- Newgioco Group, Inc. (NWGIW) Income Statement Analysis – Financial Results
- Fuud AB (publ) (FUUD.ST) Income Statement Analysis – Financial Results
- Property Perfect Public Company Limited (PF.BK) Income Statement Analysis – Financial Results
- Quaker Chemical Corporation (KWR) Income Statement Analysis – Financial Results
Laboratorios Richmond S.A.C.I.F. (RICH.BA)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.richmondlab.com
About Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company sells its products in Latin America, Africa, Asia, and the Middle East. Laboratorios Richmond S.A.C.I.F. was founded in 1935 and is headquartered in Buenos Aires, Argentina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 39.03B | 57.52B | 32.37B | 9.33B | 3.90B |
| Cost of Revenue | 18.48B | 30.34B | 22.76B | 4.78B | 2.10B |
| Gross Profit | 20.55B | 27.18B | 9.60B | 4.55B | 1.80B |
| Gross Profit Ratio | 52.66% | 47.25% | 29.67% | 48.73% | 46.19% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.21B | 4.47B | 1.58B | 684.22M | 0.00 |
| Selling & Marketing | 5.02B | 13.46B | 3.53B | 1.53B | 0.00 |
| SG&A | 6.23B | 17.94B | 5.11B | 2.22B | 1.02B |
| Other Expenses | 9.23B | 5.76B | 60.76M | 213.93M | 0.00 |
| Operating Expenses | 20.55B | 17.87B | 5.11B | 2.22B | 1.02B |
| Cost & Expenses | 33.68B | 48.21B | 27.87B | 7.00B | 3.11B |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 19.47M |
| Interest Expense | 5.31B | 4.46B | 1.45B | 506.18M | 141.34M |
| Depreciation & Amortization | 2.33B | 2.28B | 673.20M | 255.12M | 136.85M |
| EBITDA | -6.28B | 9.22B | 3.44B | 1.90B | 492.03M |
| EBITDA Ratio | -16.09% | 14.24% | 10.64% | 20.53% | 12.63% |
| Operating Income | 5.09B | 5.91B | 2.77B | 1.66B | 780.67M |
| Operating Income Ratio | 13.04% | 10.28% | 8.56% | 17.80% | 20.04% |
| Total Other Income/Expenses | -19.01B | -3.42B | -8.47M | -516.95M | -566.83M |
| Income Before Tax | -13.92B | 2.49B | 2.76B | 1.14B | 213.85M |
| Income Before Tax Ratio | -35.68% | 4.33% | 8.53% | 12.26% | 5.49% |
| Income Tax Expense | -3.00B | 1.99B | 1.59B | 410.18M | 84.69M |
| Net Income | -10.85B | 508.94M | 1.15B | 733.94M | 116.44M |
| Net Income Ratio | -27.80% | 0.88% | 3.56% | 7.87% | 2.99% |
| EPS | -134.37 | 6.30 | 14.27 | 9.09 | 1.44 |
| EPS Diluted | -134.37 | 6.30 | 14.27 | 9.09 | 1.44 |
| Weighted Avg Shares Out | 80.75M | 80.78M | 80.74M | 80.74M | 80.75M |
| Weighted Avg Shares Out (Dil) | 80.75M | 80.78M | 80.74M | 80.74M | 80.75M |
Source: https://incomestatements.info
Category: Stock Reports